Novartis 3Q10 3Q10 Revenues: $12.6 billion (+13%) 3Q10 Earnings: $2.3 billion (+10%) YTD Revenues: $36.4 billion (+16%) YTD Earnings: $7.7 billion (+26%) Comments: Branded pharma sales were up 6% to $7.6 billion in the quarter, while generic sales (the Sandoz unit) posted 18% growth to $2.2 billion and Vaccines/Diagnostics posted $600 million (+21%) in sales. Consumer Health added $1.6 billion (+9%). During the quarter, the company acquired an additional 52% of Alcon, consolidatin...